ICD-10 Coding for Neuroendocrine Tumor(E31.2M, E34.0C, E34.0U)
Explore ICD-10 coding for neuroendocrine tumors, including malignant and benign classifications, documentation requirements, and coding pitfalls.
Complete code families applicable to Neuroendocrine Tumor
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C7A.0 | Malignant carcinoid tumors | Use for confirmed malignant carcinoid tumors with site specificity. |
|
| C7A.1 | Malignant poorly differentiated neuroendocrine tumors | Use for poorly differentiated neuroendocrine carcinomas. |
|
| D3A.0 | Benign carcinoid tumors | Use for histologically confirmed benign carcinoid tumors. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutNeuroendocrine Tumor
Documentation & Coding Risks
Avoid these common issues when documenting Neuroendocrine Tumor.
Omitting Ki-67 index in documentation
Impact
Clinical: Impacts treatment decisions and prognosis., Regulatory: Non-compliance with documentation standards., Financial: Potential for denied claims due to incomplete documentation.
Mitigation
Implement checklist for pathology reports., Regular training for documentation staff.
Confusing benign and malignant neuroendocrine tumors
Impact
Reimbursement: Incorrect coding may lead to improper DRG assignment., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate clinical data reporting.
Mitigation
Verify histological reports for malignancy indicators.
Histological confirmation
Impact
Lack of histological confirmation can lead to audit findings.
Mitigation
Ensure all tumor diagnoses are supported by histological reports.